Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of OPC-41061 1% powder formulation
jRCT1080222790Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of tolvaptan (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Bioequivalence of OPC-41061 1% powder vs 15 mg tablet. Started Mar 2015; status: completed.
02
Drugs
tolvaptan
Beyond the preview
Go deeper on jRCT1080222790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222790.